ArticleEuropean journal of medicinal chemistry2023

Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy.

Ryan L Gonciarz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.